Key result
Type III interferons protect mucosal barriers by balancing tissue tolerance and immune resistance against pathogens.
Why the study?
Type III IFNs were long believed to play redundant roles with type I IFNs, but display unique traits as primary protectors of mucosal barrier integrity.
This review highlights the unique immunomodulatory properties of Type III interferons in protecting barrier integrity at mucosal sites.
Type III IFNs, or IFN-λ, are the newest members of the IFN family and were long believed to play roles that were redundant with those of type I IFNs. However, IFN-λ displays unique traits that delineate them as primary protectors of barrier integrity at mucosal sites. This unique role stems both from the restricted expression of IFN-λ receptor, confined to epithelial cells and to a limited pool of immune cells, and from unique immunomodulatory properties of IFN-λ. Here, we discuss recent findings that establish the unique capacity of IFN-λ to act at the barriers of the host to balance tissue tolerance and immune resistance against viral and bacterial challenges.
No takes yet. Share an insight, caveat, or question.
Broggi et al. (2019) conducted a review in Viral and bacterial challenges. Type III interferons (IFN-λ) was evaluated. Type III interferons (IFN-λ) act as primary protectors of barrier integrity at mucosal sites, balancing tissue tolerance and immune resistance against viral and bacterial challenges.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from The Journal of Experimental Medicine